Company Blog

Innovation and Flexibility Drive Success During the COVID-19 Pandemic

In these exceptional circumstances, what we do matters more than ever.

Grifols Recombinant Protein CDMO is focused on the same flexibility and problem-solving spirit we use daily to rapidly produce custom proteins to battle the current pandemic.

At Grifols Recombinant Protein CDMO, we produce recombinant proteins for further manufacture that are used in assays to screen donated blood for viral infections, as well as develop manufacturing processes for novel therapeutics. In 2020, we directed resources toward developing new antigens for SARS-CoV-2 immunoassays. While pursuing this crucial endeavor, we also took comprehensive measures to ensure shipments of products and the provision of services.

READ MORE BY FILLING OUT THE FORM >>>>>

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters